DAVIES



Hillel W. Rosen
Partner

Office
Montréal

Tel
514.841.6443

Email
hrosen@dwpv.com

Expertise
Mergers and Acquisitions
Real Estate
Corporate
Life Sciences

Bar Admissions
Québec, 1988

For more than 30 years, Hillel has been a key adviser to leading Canadian and foreign companies on their transactional matters.

Clients in diverse sectors, including life sciences and commercial real estate, value his thorough understanding of their businesses, his responsiveness and his pragmatic approach to challenging and time-sensitive transactions.

Hillel is recognized for both his corporate commercial law expertise as well for his command of life sciences transactions. An exceptional corporate lawyer, he is sought out by both domestic and multinational players.

Hillel has been a long-time counsel to several of Canada's leading specialty pharmaceutical companies.

Hillel is a member of our firm-wide Finance Committee.

Representative Work

Paladin Labs Inc.
Acted for **Paladin Labs Inc.** in connection with its acquisition by Endo Health Solutions Inc. in a stock and cash transaction valued at approximately $3 billion.

Searchlight Pharma Inc.
Acted for the shareholders of **Searchlight Pharma Inc.**, a top-growth Canadian specialty and innovative branded pharmaceutical company, in connection with the sale of their 100% interest to Apotex Inc.

Knight Therapeutics Inc.
Acted for a wholly owned subsidiary of **Knight Therapeutics Inc.**, in the US$125 million cash sale of its Neglected Tropical Disease Priority Review Voucher, which was granted by the U.S. Food and Drug Administration with the approval of Impavidor (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis, to Gilead Sciences, Inc.

Knight Therapeutics Inc.
Acted for **Knight Therapeutics Inc.** in its transformative acquisition of all of the issued and outstanding shares of Biotoscana Investments S.A., a Luxembourg company listed on the Brazilian stock exchange, for an aggregate purchase price of $369 million.

Kimco Realty Corporation
Acted for **Kimco Realty Corporation** in connection with the sale of its interests in 22 shopping centres to RioCan Real Estate Investment Trust for a purchase price of $715 million.

The Cadillac Fairview Corporation Limited
Acted for **The Cadillac Fairview Corporation Limited** with respect to the establishment of a joint venture for the development of **Tour des Canadiens 2**, a 49 storey residential condominium building located across from the Bell Centre in the heart of downtown Montréal and represented the joint venture, **Tour des Canadiens 2 S.E.C.**, in connection with that development. Davies also represented **The Cadillac Fairview Corporation Limited** in the establishment of a joint venture in the development of **Tour des Canadiens 3**, a 55-storey residential condominium building, and acted for the joint venture, **Tour des Canadiens 3 S.E.C.**, in that development.

DAVIES

Hillel W. Rosen
Partner

Office
Montréal

Tel
514.841.6443

Email
hrosen@dwpv.com

Canadian Forum Investments Inc.

Acted for **Canadian Forum Investments Inc.** in its acquisition of the Montreal Forum historic property in a transaction valued at $45.2 million.

Kimco Realty Corporation

Acted for **Kimco Realty Corporation** in connection with the sale by its affiliates of co-ownership interests and partnership interests in a portfolio of 18 shopping centres located in Alberta and British Columbia to Anthem Properties Group Ltd. for $413 million dollars.

Family Shareholders of Dorel Industries Inc.

Acting for **the controlling family shareholders**, who partnered with Cerberus Capital Management, L.P. in the privatization of Dorel Industries Inc., a TSX-listed company, by way of plan of arrangement.

Rosenbloom Groupe Inc. and Hymopack Ltd.

Acted for **Rosenbloom Groupe Inc. and Hymopack Ltd.** in the sale of 100% of their equity interests to wholly owned subsidiaries of ProAmpac Packaging Canada Inc.

Altus Formulation Inc.

Acted for **Altus Formulation Inc.** in its joint venture agreement with Tetra Bio-Pharma Inc. under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.

TALLC Corporation Inc.

Acted for **TALLC Corporation Inc.**, a Montréal-based developer of ophthalmic medicines, regarding its strategic collaboration and licensing agreement with IACTA Pharmaceuticals for the use and future clinical development of TALLC's proprietary SmartCelle micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development.

Searchlight Pharma Inc.

Acted for **Searchlight Pharma Inc.**, a Montréal-based specialty healthcare company, in its acquisition of ERFA Canada 2012 Inc., a distributor of niche pharmaceutical products across Canada that addresses underserved medical indications.

Knight Therapeutics Inc.

Acted for **Knight Therapeutics Inc.** (TSX: GUD), a pan-America specialty pharmaceutical company, in its acquisition from Novartis of the exclusive rights to manufacture, market and sell Exelon (rivastigmine patch, capsules and solution) in Canada and Latin America, for the purchase price of US$168 million and an additional milestone payment of up to US$12 million on the achievement of certain conditions.

Ayana Pharma Ltd.

Advising **Ayana Pharma Ltd.** on various commercial matters.

Faubourg Boisbriand Shopping Centre Holdings Inc. (Kimco Realty Corporation)

Acted for **Faubourg Boisbriand Shopping Centre Holdings Inc.** (a joint venture among Kimco Realty Corporation, Cherokee Partners and Sterling Centrecorp) in connection with a $165 million construction credit facility in respect of the Faubourg Boisbriand lifestyle retail complex in Boisbriand, Québec.

DAVIES

Hillel W. Rosen
Partner

Office
Montréal

Tel
514.841.6443

Email
hrosen@dwpv.com

Knight Therapeutics International S.A.

Acted for **Knight Therapeutics International S.A.** in negotiating a complex supply and distribution agreement with Eton Pharmaceuticals granting exclusive U.S. commercialization rights for IMPAVIDO, the only FDA-approved oral treatment for certain forms of leishmaniasis.

Recognitions

Chambers Canada
Corporate/Commercial: Québec; Life Sciences: Corporate/Commercial

IFLR1000
Mergers and Acquisitions; Real Estate Acquisitions

Lexpert 500 Cross Border
Corporate Mid-Market

Lexpert Special Edition
Health Sciences; M&A

Lexpert (CLLD)
Corporate Mid-Market
Most Frequently Recommended

Lexpert (CLLD)
Corporate Commercial Law; Mergers and Acquisitions

Best Lawyers Canada
Banking and Finance Law; Biotechnology & Life Sciences

Best Lawyers Canada
Corporate Law; Mergers and Acquisitions Law; Real Estate Law

Insights

Davies Earns Distinction at 2026 Life Sciences Awards
Sep 11, 2026

Davies Lawyers Recognized by *Best Lawyers*
Sep 3, 2026

Lexpert Recognizes Davies' Health Sciences Expertise
Jul 8, 2026

Lexpert Recognizes Davies' M&A Expertise
Apr 15, 2026

Lexpert Affirms Davies' Position as a Leading Firm
Mar 17, 2026

Lexpert 500 Guide Recognizes Davies
Jan 14, 2026

Lexpert Special Edition Recognizes Davies' Expertise in M&A
Apr 16, 2025

Nine Davies Lawyers Recognized as Leaders in Health Sciences
Jun 10, 2021

Education

DAVIES

Hillel W. Rosen
Partner

Office
Montréal

Tel
514.841.6443

Email
hrosen@dwpv.com

University of Oxford, MA, 1987
McGill University, BCL/LLB (Double Gold Medallist), 1985

Bar Admissions

Québec, 1988

Community Involvement

McGill University Faculty of Law

Board Memberships

Jewish Public Library, honorary director
Akiva School, director